Related Experiment Video
Updated: Mar 17, 2026
06:50
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
Published on: September 5, 2025
585
Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score
Vinod S Hegade1,2,3, Amardeep Khanna4,5, Lucy J Walker5
1NIHR Newcastle Biomedical Research Centre, Framlington Place, Newcastle University, Newcastle upon Tyne, UK. Vinod.hegade@ncl.ac.uk.
Digestive Diseases and Sciences
|July 21, 2016
Summary
Long-term fenofibrate (FF) plus ursodeoxycholic acid (UDCA) improved alkaline phosphatase (ALP) in primary biliary cholangitis (PBC) patients. However, this combination therapy did not significantly reduce long-term liver disease prognosis scores.
Area of Science:
- Hepatology
- Pharmacology
- Clinical Medicine
Background:
- Primary biliary cholangitis (PBC) is a chronic liver disease.
- Ursodeoxycholic acid (UDCA) is the standard first-line treatment.
- Fenofibrate (FF) is considered for patients with inadequate response to UDCA.
Purpose of the Study:
- To evaluate the long-term biochemical outcomes of combining FF with UDCA in PBC patients.
- To assess the impact of this combination therapy on predicted prognosis using the UK-PBC Risk Score.
Main Methods:
- Retrospective cohort study of PBC patients treated with FF + UDCA after biochemical response failure.
- Analysis of liver and renal biochemical indices and UK-PBC Risk Score at multiple time points up to 60 months.
- Assessment of biochemical response using POISE trial criteria.
Main Results:
- Significant reduction in alkaline phosphatase (ALP) observed at 12, 24, and 36 months (p < 0.05).
- Over 75% of patients achieved ALP response criteria at all time points.
- No significant improvement in UK-PBC Risk Scores; no significant renal impairment or adverse events reported.
Conclusions:
- Long-term FF + UDCA therapy is safe and effective for improving ALP in PBC patients.
- This combination therapy did not significantly alter the predicted long-term prognosis for liver-related complications.
More Related Videos
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
315
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
315
01:17Chronic Bowel Disorders: Introduction
891
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
891
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
1.0K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
1.0K
01:28Pulmonary Tuberculosis V
737
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
737
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K